Deliver eConsent to sites and study participants around the globe with confidence
This article delves into the transformative impact of Interactive Response Technology (IRT) platforms on cell and gene therapy (CGT) trials. It highlights the unique logistical challenges of CGT trials, where each treatment is tailored to individual patients, requiring meticulous tracking and management throughout the supply chain. IRT platforms offer comprehensive solutions by adapting to specific trial requirements, ensuring precise tracking, temperature control, and real-time status monitoring.
The article emphasizes the importance of a consultative partnership approach between sponsors and technology providers to navigate the complexities of CGT trials successfully. It also discusses the critical role of data integrity and regulatory compliance in maintaining trial validity. As the field of gene therapy evolves, IRT platforms continue to innovate, supporting the advancement of personalized medicine and bringing revolutionary treatments to patients safely and efficiently.
Save upwards of $20,000 a month through automated supply optimization
Deliver eConsent to sites and study participants around the globe with confidence
Improve study quality, accelerate decision making and reduce site and sponsor burden by harnessing the power of IQVIA’s integrated Interactive Response Technology (IRT) and electronic Clinical Outcome Assessment (eCOA) solution.
Power your decentralized trial with an agile randomization and trial supply management solution that supports supply flexibility and optimization as well as adaptable direct to patient options.